Involvement of σ1 receptors in methamphetamine-induced behavioral sensitization in rats

Neuroscience Letters

Volumn 289, Issue 1, 2000, Pages 21-24

  Takahashi, S ^a   Miwa, T ^a   Horikomi, K ^a  

^a Mitsui Pharmaceuticals Inc   (Japan)

Author keywords

Behavioral sensitization; Deterioration; Development; Methamphetamine; MS 377; 1 Ligand

Indexed keywords

1 (4 CHLOROPHENYL) 3 [4 (2 METHOXYETHYL)PIPERAZIN 1 YL]METHYL 2 PYRROLIDINONE TARTRATE; HALOPERIDOL; LIGAND; METHAMPHETAMINE; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; STEREOTYPY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; INJECTIONS, INTRAPERITONEAL; MALE; METHAMPHETAMINE; PIPERAZINES; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, SIGMA; SCHIZOPHRENIA; STEREOTYPED BEHAVIOR; TARTRATES;

EID: 0034726011     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01258-1     Document Type: Article

References (15)

1. 1A receptor. Eur. J. Pharmacol. 204:1991;21-28.
2. Costall B., Naylor R.J., Olley L.E. The substantia nigra and stereotyped behavior. Eur. J. Pharmacol. 18:1972;95-106.
3. Ellinwood E.H., Sudilovski A., Nelson L.J. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am. J. Psychiatry. 34:1973;1088-1093.
4. Gewirtz G.R., Gorman J.M., Volavka J., Macaluso J., Gribkoff G., Taylor D.P., Borison R. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 10:1994;37-40.
5. Itzhak Y. Repeated methamphetamine-treatment alters brain receptors. Eur. J. Pharmacol. 230:1993;243-244.
6. Kuchenski R., Leith N.J. Chronic amphetamine: is dopamine a link in or a mediator of the development of tolerance and reverse tolerance? Pharmacol. Biochem. Behav. 15:1981;405-413.
7. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
8. Takahashi S., Sonehara K., Takagi K., Miwa T., Horikomi K., Mita N., Nagase H., Iizuka K., Sakai K. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors. Psychopharmacology. 145:1999;295-302.
9. Tella S.R. Differential blockade of chronic vs. acute effect of intravenous cocaine by dopamine receptor antagonists. Pharmacol. Biochem. Behav. 48:1994;151-159.
10. Ujike H., Kanzaki A., Okumuma K., Akiyama K., Otsuki S. Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci. 50:1992;PL129-134.
11. Ujike H., Kuroda S., Otsuki S. σ receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 296:1996;123-128.
12. Ujike H., Okumura K., Zushi Y., Akiyama K., Otsuki S. Persistent supersensitivity of s receptors develops during repeated methamphetamine treatment. Eur. J. Pharmacol. 211:1992;323-328.
13. Ujike H., Onoue T., Akiyama K., Hamamura T., Otsuki S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology. 98:1989;89-92.
14. Ujike H., Tsuchida K., Akiyama K., Otsuki S. Supersensitivity of σ receptors after repeated administration of cocaine. Life Sci. 51:1992;PL31-36.
15. Weiss S.R., Post R.M., Pert R., Woodward R., Murman D. Context-dependent cocaine sensitization: differential effect of haloperidol on development vs. expression. Pharmacol. Biochem. Behav. 34:1989;655-661.